Protagonist Stock 120%, Fund Outlook and Exit Signals
A hedge fund's sizable exit from Protagonist Therapeutics highlights how insiders and funds shape biotech stock moves...
Identify essential line items for unexpected bills and set aside funds to smooth out financial shocks. A clear plan reduces anxiety and keeps spending in check.
15,931 articlesA hedge fund's sizable exit from Protagonist Therapeutics highlights how insiders and funds shape biotech stock moves...
Two traders file a civil suit accusing Polymarket of misresolving a Strategy bitcoin sale market after a late May dis...
Bitcoin briefly flirted with the $70,000 level while the broader crypto market posted a solid advance. Analysts warn ...
As July 22 approaches, investors face a familiar crossroads: take a position before earnings or wait for the full pic...
A 58-year-old with $800,000 saved is considering retirement in five years without Social Security, weighing a bridge ...
A popular financial talk show outlined a bold, nominal projection for a 29-year-old with $550k saved to reach $5 mill...
CoreWeave is set to report Q4 2025 results after the close, with investors weighing 2026 guidance amid a legal backdr...
The wheaton precious metals stock faced a sharp June pullback as gold and silver paused. This article breaks down the...
As 2025 closes, star bulk (sblk) enters a new chapter. This guide breaks down the Q4 2025 results, fleet strategy, ba...
The Nasdaq 100 ETF is seeing its busiest month in years as traders chase SpaceX exposure, aided by new weighting rule...
Shiba Inu dropped in double digits for a short window and then settled. This guide explains why shiba sank more than ...
ARK Invest doubled down on SpaceX after a market pullback, funding the move by trimming Alibaba. The trade underscore...